Relay Therapeutics, Inc. reported its financial results for the first quarter of 2026, revealing a total revenue of $3 million, a significant decrease from $7.7 million in the same period last year. The decline in revenue is attributed to reduced milestone payments from its licensing agreement with Elevar Therapeutics, which accounted for the majority of the company's revenue. Operating expenses for the quarter were $81.6 million, down from $92.5 million in the prior year, primarily due to a reduction in general and administrative costs. The company recorded a net loss of $73.3 million, an improvement from the $77.1 million loss reported in the first quarter of 2025.
In terms of operational developments, Relay Therapeutics has made strategic advancements in its clinical pipeline. The company is actively developing its lead product candidate, zovegalisib (RLY-2608), which is currently in clinical trials for various cancer indications. The company has also initiated a global Phase 1/2 clinical trial for zovegalisib in patients with PIK3CA-related overgrowth spectrum. As of March 31, 2026, Relay Therapeutics had cash, cash equivalents, and investments totaling $642.1 million, which the company believes will fund its operations into 2029.
The company has also seen changes in its employee headcount, with a focus on streamlining its research organization. As of the end of the first quarter, Relay Therapeutics had 189.2 million shares of common stock outstanding, reflecting an increase from the previous year due to recent stock offerings. The company raised approximately $137.1 million in net proceeds from at-the-market offerings during the quarter, which will support its ongoing clinical development activities.
Looking ahead, Relay Therapeutics faces several material risks, including the uncertainty of clinical trial outcomes and the need for additional funding to support its operations. The company has indicated that it may need to raise substantial additional capital to continue its product development programs. Relay Therapeutics has not yet commercialized any products and does not expect to generate revenue from product sales for several years. The company remains focused on advancing its clinical trials and exploring new therapeutic opportunities while navigating the competitive landscape of the biotechnology industry.
Overall, Relay Therapeutics continues to develop its innovative pipeline while managing its financial resources carefully. The company’s future performance will depend on the successful execution of its clinical trials and the ability to secure additional funding as needed.
About Relay Therapeutics, Inc.
Relay Therapeutics is a biopharmaceutical company specializing in precision medicine through its Dynamo platform, which integrates computational and experimental techniques to target previously intractable proteins. Its focus includes oncology and genetic diseases, developing small molecule therapies such as mutant-selective kinase inhibitors. The company advances pipeline candidates, collaborates with partners like Pfizer and Elevar, and aims to deliver targeted, innovative treatments for life-threatening conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.